論文資料
1. 研究刊登於Nature期刊
明尼蘇達州伊根市 — 2011年4月27日 — 一項新發表於Nature期刊並登上封面故事的研究提到了Biothera的葡聚多醣體，以及有關這種獨特的免疫調節化合物如何活化免疫系統以保護人體的最新發現。
該研究證實並非所有的葡聚多醣體都是相同的。以大衛‧安德希爾博士(David Underhill, Ph.D.)博士所領導的研究團隊證明葡聚多醣體的大小和分子結構是它能結合受體以及後續造成先天免疫細胞反應的關鍵。安德希爾博士和他的研究團隊發現只有特定的葡聚多醣體會和特別的受體(Dectin-1)結合，而其它的葡聚多醣體構造就不行。
2011年4月號Nature期刊封面故事：
先天免疫系統如何在眾多死去的真菌殘骸中偵測到仍有致病性的真菌
(只有顆粒狀的葡聚多醣體 "Biothera, Wellmune WGP®"才能在與巨噬細胞表面的Dectin-1受體結合後啟動巨噬細胞的吞噬作用;其他小分子的葡聚多醣體或是葡聚多醣體的碎片則無法做到。)
“本研究證實了葡聚多醣體的結構非常重要”，Biothera的研發部副總裁威廉‧葛洛斯曼醫師(William Grossman, M.D., Ph.D.)說道：“即便是些微的葡聚多醣體分子的差異都會影響到用來引起不同撲殺機制的訊息通路。這些資料擴展了我們先前的研究並指出我們的某些其他葡聚多醣體結構能和CR3結合，引發出個別而又獨特的機制。”
該項研究顯示Dectin-1受體能區分出究竟是直接接觸到微生物還是偵測到位於遠處的微生物，這種區分使得它能夠啟動有效的微生物撲殺反應。當與Biothera的Wellmune WGP® 結合後，源自Dectin-1的訊號能夠活化免疫細胞來進行吞噬作用，這是用來辨識和摧毀病原菌的一種機制。
身為 Cedars-Sinai 醫學中心IBD暨免疫生物學研究學院副教授的安德希爾博士 (Dr. Underhill) 說：“由於Biothera公司有能力分離、修改並了解這些葡聚多醣體化合物的特性，我們才有可能進行這項研究。”
Biothera是美國一家在葡聚多醣體研究方面居先驅地位的生物科技公司。該公司已開發出應用在醫藥上的葡聚多醣體和用在食品、飲料和營養補充品上做為免疫健康成分的葡聚多醣體。該公司的Imprime PGG® 是一種注射針劑藥物，目前正在做結直腸癌第三期人體臨床試驗和多項非小細胞肺癌第二期人體臨床試驗的階段。Biothera的Wellmune WGP® 是一種可用在機能性食品、飲料和營養補充品上的食品級免疫健康原料，目前行銷超過30個國家。
Biothera保健部門研發資深副總裁唐‧科克斯 (Don Cox, Ph.D.) 說：“我們很高興能夠對有關葡聚多醣體的結構和它們與功能性機制之間的關係週邊持續增加中的研究做出一些貢獻。”
刊載於Nature期刊上的論文標題叫做 “Activation of the Innate Immune Receptor Dectin-1 upon Formation of a ‘Phagocytic Synapse’”。全文可在Nature期刊的網站被查詢到。
營養製劑達人翻譯自Biothera新聞稿(2011/4/27)，原始文章摘錄自Biothera網站：
New Research on Biothera Beta Glucans is Published in Nature
你也可以到PUBMED網站上找到這篇文章的摘要及全文供下載：
New Research on Biothera Beta Glucans is Published in Nature
EAGAN, MN — April 27, 2011 — A new study published today as the cover story in the journal Nature features Biothera’s beta glucans and new discoveries about how these unique immunodulating compounds prime the innate immune system to protect the body.
This research confirmed that not all beta glucans are alike. Researchers led by David Underhill, Ph.D. demonstrated that beta glucan size and molecular structure is critical to receptor binding and the resulting innate immune cell response. Dr. Underhill and his research team found that specific beta glucan structures bind to a particular receptor (Dectin-1) while other beta glucans structures did not.
“This research demonstrates that the structure of beta glucans matters,” said William Grossman, M.D., Ph.D., Biothera senior vice president of Research & Development. “Even slight molecular differences in beta glucans affect the signaling pathways used to induce different killing mechanisms. These data expand on our previous research showing that some of our other beta glucan structures bind to CR3, inducing separate and unique mechanisms.”
The study shows that Dectin-1 distinguishes between direct microbial contact and detection of microbes at a distance, a distinction that enables effective microbial killing responses. When bound to Biothera's Wellmune WGP®, Dectin-1 signaling primed immune cells for phagocytosis, a mechanism used to recognize and destroy pathogens.
“This research was possible because of Biothera’s capability to isolate, modify and characterize these beta glucan compounds,” said Dr. Underhill, associate professor, IBD and Immunobiology Research Institute, Cedars-Sinai Medical Center.
Biothera is a U.S. biotechnology company that is pioneering beta glucan research. The company has developed glucans as both pharmaceutical applications and immune health ingredients for foods, beverages and supplements. The company’s Imprime PGG® is an injectable drug that is currently in a Phase III clinical trial for colorectal cancer and multiple Phase II trials for non small cell lung cancer. Biothera’s Wellmune WGP® is a food-grade, immune-health ingredient for functional foods, beverages and supplements in more than 30 countries.
“We’re pleased to be able to contribute to the growing body of research surrounding beta glucan structures and their relationship to functional mechanisms,” said Don Cox, Ph.D., senior vice president, Biothera Healthcare Research & Development.
The title of the Nature paper is “Activation of the Innate Immune Receptor Dectin-1 upon Formation of a ‘Phagocytic Synapse.’” The paper is accessible on the Nature website.
Wellmune貝塔葡聚醣
貝塔葡聚醣Biothera
公司介紹影片介紹(2)
影片介紹(3)
影片介紹(4)
影片介紹(5)
影片介紹(6)
沒有留言:
張貼留言